We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+6.97%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$2.27B
AUM Growth
+$205M
Cap. Flow
+$122M
Cap. Flow %
5.35%
Top 10 Hldgs %
63.25%
Holding
50
New
2
Increased
11
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
PRGO icon
Perrigo
PRGO
+$59.3M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$59M
3
VTRS icon
Viatris
VTRS
+$50.4M
4
GILD icon
Gilead Sciences
GILD
+$36.6M
5
THC icon
Tenet Healthcare
THC
+$35.8M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$66.5M
2
CI icon
Cigna
CI
+$64M
3
LDRH
LDR HOLDINGS CORP COM STK
LDRH
+$50.8M
4
COR icon
Cencora
COR
+$49.6M
5
NUVA
NuVasive, Inc.
NUVA
+$44.8M

Sector Composition

Rank Sector Weight
1 Healthcare 57.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$784B
$487M 21.4%
2,250,000
+1,250,000
+125% +$270M
TEVA icon
2
Teva Pharmaceuticals
TEVA
$41.2B
$184M 8.09%
4,000,000
+1,130,000
+39% +$59M
VTRS icon
3
Viatris
VTRS
$20.7B
$148M 6.49%
3,873,000
+1,133,000
+41% +$50.4M
PRGO icon
4
Perrigo
PRGO
$1.43B
$112M 4.93%
1,213,600
+643,600
+113% +$59.3M
GILD icon
5
Gilead Sciences
GILD
$163B
$94.9M 4.17%
1,200,000
+450,000
+60% +$36.6M
TEVA icon
6
CALL
Teva Pharmaceuticals
TEVA
$41.2B
$92M 4.05%
2,000,000
+875,000
+78% +$45.7M
ENDP
7
DELISTED
Endo International plc
ENDP
$85.4M 3.76%
4,240,000
-805,000
-16% -$16M
SEM
8
DELISTED
Select Medical
SEM
$81.3M 3.58%
11,182,400
+835,200
+8% +$5.31M
GILD icon
9
CALL
Gilead Sciences
GILD
$163B
$79.1M 3.48%
1,000,000
– –
MDCO
10
DELISTED
Medicines Co
MDCO
$75.5M 3.32%
2,000,000
– –
CSII
11
DELISTED
Cardiovascular Systems, Inc.
CSII
$71.2M 3.13%
3,000,000
-1,100,000
-27% -$24.1M
GHDX
12
DELISTED
Genomic Health, Inc.
GHDX
$71.1M 3.13%
2,458,100
– –
BKD icon
13
Brookdale Senior Living
BKD
$3.49B
$69.8M 3.07%
4,000,000
– –
OFIX icon
14
Orthofix Medical
OFIX
$477M
$64.2M 2.82%
1,500,000
– –
LIVN icon
15
LivaNova
LIVN
$4.45B
$60.1M 2.64%
1,000,000
-200,000
-17% -$11.5M
CYH icon
16
Community Health Systems
CYH
$391M
$57.7M 2.54%
5,000,000
+1,550,000
+45% +$17.9M
THC icon
17
Tenet Healthcare
THC
$21.8B
$56.6M 2.49%
2,500,000
+1,375,000
+122% +$35.8M
NKTR icon
18
Nektar Therapeutics
NKTR
$2.41B
$55M 2.42%
213,333
-70,000
-25% -$18M
UAM
19
DELISTED
Universal American Corp
UAM
$44.9M 1.98%
5,875,000
– –
ALKS icon
20
Alkermes
ALKS
$8.39B
$44.1M 1.94%
937,300
– –
BHC icon
21
Bausch Health
BHC
$2.25B
$31.2M 1.37%
1,271,500
-384,500
-23% -$9.95M
CNMD icon
22
CONMED
CNMD
$1.41B
$30M 1.32%
+750,000
New +$31.8M
OPCH icon
23
Option Care Health
OPCH
$3.36B
$29.4M 1.29%
2,545,000
– –
PTCT icon
24
PTC Therapeutics
PTCT
$6.26B
$28M 1.23%
2,000,000
+500,000
+33% +$4.06M
NVTA
25
DELISTED
Invitae Corporation
NVTA
$21.4M 0.94%
2,442,122
-304,500
-11% -$2.56M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Camber Capital Management held 50 positions worth $2.27B, up 9.9% from $2.07B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Camber Capital Management deployed $122M of net new capital in Q3 2016, opening 2 new positions and adding to 11 existing holdings. Its largest new stake was CONMED: 750,000 shares worth $30M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 65% a quarter earlier.

On the sell side, the largest reduction was Endologix Inc, an estimated $25.6M trimmed.

  • Camber Capital Management's largest Q3 2016 buy was CONMED: 750,000 shares worth $30M.
  • Camber Capital Management added most to Perrigo in Q3 2016, an estimated $59.3M increase.
  • Camber Capital Management's biggest Q3 2016 reduction was Endologix Inc, cutting an estimated $25.6M.
  • Camber Capital Management fully exited Biogen in Q3 2016, selling an estimated $66.5M.
  • Camber Capital Management's ten largest holdings make up 63% of its $2.27B portfolio in Q3 2016.
  • Camber Capital Management opened 2 new positions and closed 13 in Q3 2016.
  • Camber Capital Management's portfolio value rose 9.9% quarter-over-quarter to $2.27B.

Based on Camber Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.